Richard Sainson
@rcasainson.bsky.social
Excited about science, immunology, tumour microenvironment and new therapies.🇫🇷🇬🇧🇪🇺 ❤️🔬
Nice read about the story of Henri Termeer who changed research of rare disease for good. #Biotech #RareDiseases
October 5, 2025 at 12:11 PM
Nice read about the story of Henri Termeer who changed research of rare disease for good. #Biotech #RareDiseases
Slides on HARMONi Phase III trial on ivonescimab + platinum-doublet chemotherapy in patients with EGFR-mutated advanced NSCLC... The story continues! www.smmttx.com/wp-content/u...
September 15, 2025 at 4:00 PM
Slides on HARMONi Phase III trial on ivonescimab + platinum-doublet chemotherapy in patients with EGFR-mutated advanced NSCLC... The story continues! www.smmttx.com/wp-content/u...
That was a disturbing read!!!
August 14, 2025 at 8:02 AM
That was a disturbing read!!!
Anti PD-L1 + anti-TIGIT in NSCLC…. Not convincing….?
May 1, 2025 at 4:44 AM
Anti PD-L1 + anti-TIGIT in NSCLC…. Not convincing….?
Easy read for a Sunday evening…🇫🇷📚🩻
November 17, 2024 at 10:18 PM
Easy read for a Sunday evening…🇫🇷📚🩻
Our recent poster on the therapeutic potential of ADV-101, a first in class #ADC targeting #IL1RAP in esophageal cancer is now on our website 🔬👩🔬
advesya.com/adv-101-prec...
advesya.com/adv-101-prec...
November 16, 2024 at 5:32 AM
Our recent poster on the therapeutic potential of ADV-101, a first in class #ADC targeting #IL1RAP in esophageal cancer is now on our website 🔬👩🔬
advesya.com/adv-101-prec...
advesya.com/adv-101-prec...